Vanta Bioscience Past Earnings Performance
Past criteria checks 0/6
Vanta Bioscience's earnings have been declining at an average annual rate of -76.5%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 9.7% per year.
Key information
-76.5%
Earnings growth rate
-76.5%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | -9.7% |
| Return on equity | -43.0% |
| Net Margin | -43.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vanta Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 103 | -45 | 53 | 0 |
| 30 Jun 23 | 86 | -55 | 51 | 0 |
| 31 Mar 23 | 69 | -65 | 48 | 0 |
| 31 Dec 22 | 72 | -45 | 37 | 0 |
| 30 Sep 22 | 71 | -25 | 24 | 0 |
| 30 Jun 22 | 84 | -12 | 27 | 0 |
| 31 Mar 22 | 100 | 1 | 33 | 0 |
| 31 Dec 21 | 101 | 2 | 34 | 0 |
| 30 Sep 21 | 101 | 4 | 32 | 0 |
| 30 Jun 21 | 101 | 4 | 30 | 0 |
| 31 Mar 21 | 100 | 4 | 31 | 0 |
| 31 Dec 20 | 111 | 5 | 38 | 0 |
| 30 Sep 20 | 121 | 5 | 45 | 0 |
| 30 Jun 20 | 131 | 8 | 50 | 0 |
| 31 Mar 20 | 141 | 10 | 55 | 0 |
| 31 Dec 19 | 139 | 10 | 54 | 0 |
| 30 Sep 19 | 137 | 9 | 54 | 0 |
| 30 Jun 19 | 131 | 8 | 50 | 0 |
| 31 Mar 19 | 124 | 7 | 46 | 0 |
| 31 Dec 18 | 110 | 5 | 40 | 0 |
| 30 Sep 18 | 95 | 3 | 34 | 0 |
| 30 Jun 18 | 68 | 2 | 25 | 0 |
| 31 Mar 18 | 40 | 0 | 17 | 0 |
Quality Earnings: 540729 is currently unprofitable.
Growing Profit Margin: 540729 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540729 is unprofitable, and losses have increased over the past 5 years at a rate of 76.5% per year.
Accelerating Growth: Unable to compare 540729's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 540729 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: 540729 has a negative Return on Equity (-42.99%), as it is currently unprofitable.